Acacia Pollen Acer Negundo Pollen Acer Rubrum Poll

證據等級: L5

預測適應症: 0 個

Multi-Component Allergen Extract Panel: Allergy Immunotherapy — No TxGNN Prediction Available

One-Sentence Summary

This product is a multi-component allergen extract containing 50 distinct allergen sources (tree, grass, and weed pollens, plus several botanical roots), intended for use in allergy immunotherapy or allergy diagnostic testing. The TxGNN model did not generate any drug repurposing predictions for this entry, most likely because the compound could not be mapped to a single DrugBank node or a canonical drug entity. Without a prediction to evaluate, this report documents the data gaps and recommends remediation before further analysis.

Quick Overview

Item	Content
Original Indication	Allergen immunotherapy / allergy diagnostic panel (inferred from composition)
Predicted New Indication	— (no TxGNN prediction generated)
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction only; no actual repurposing studies
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This entry is not a conventional single-molecule drug; it is a 50-component allergen extract mixture consisting of:

Tree pollens (Acacia, Acer spp., Betula, Carya spp., Celtis, Fraxinus, Juglans, Juniperus, Ligustrum, Liquidambar, Morus, Pinus, Platanus, Populus spp., Quercus spp., Salix, Taxodium, Ulmus)
Grass pollens (Agrostis, Cynodon, Dactylis, Festuca, Lolium, Paspalum, Poa, Sorghum)
Weed/forb pollens (Amaranthus spp., Ambrosia spp., Artemisia, Baccharis, Chenopodium, Iva, Plantago, Rumex, Urtica, Xanthium)
Botanical root/whole-plant extracts (Baptisia tinctoria root, Echinacea, Fenugreek leaf, Goldenseal, Myrrh, Phytolacca americana root)

The TxGNN knowledge graph model operates on individual DrugBank-mapped small molecules or biologics. A heterogeneous allergen panel of this nature:

Has no single DrugBank ID — confirmed null in the evidence pack.
Cannot be represented as a single node in the drug–disease graph.
Therefore, the repurposing scoring pipeline produced zero prediction candidates.

Currently, detailed mechanism of action data is not available. Based on known information, each component in this mixture represents a different immunological antigen; collectively the mixture is designed to desensitize the immune system through repeated low-dose antigen exposure (subcutaneous immunotherapy, SCIT) or to serve as a diagnostic skin-test panel.

Clinical Trial Evidence

Currently no related clinical trials registered for this multi-component combination as a repurposing candidate.

Literature Evidence

Currently no related literature available for TxGNN-driven repurposing of this allergen panel.

US Market Information

This product has no registered NDA or market authorisation in the US according to the evidence pack. Individual allergen extracts (e.g., single-source grass or tree pollen) are regulated by the FDA Center for Biologics Evaluation and Research (CBER) under a separate biologics licensing pathway, but the specific 50-allergen combination listed here does not correspond to any identifiable licensed product in the data queried.

Safety Considerations

Please refer to the package insert for safety information.

(All safety fields — key warnings, contraindications, and drug–drug interactions — returned no data in this evidence pack.)

Conclusion and Next Steps

Decision: Hold

Rationale: This entry cannot be meaningfully evaluated as a drug repurposing candidate in its current form. The product is a multi-component allergen mixture with no single molecular identity, no DrugBank mapping, no TxGNN prediction, and no US market authorisation — there is no repurposing signal to assess.

To proceed, the following is needed:

Decompose into individual components — Run TxGNN predictions separately for each of the 50 allergen sources that have known small-molecule or biologic equivalents (e.g., Echinacea, Goldenseal berberine, Urtica dioica lectins, Fenugreek saponins, Myrrh resin acids).
Obtain DrugBank IDs — Map botanically active constituents (e.g., berberine from Goldenseal, hydrastine, echinacosides) to individual DrugBank nodes to enable knowledge-graph scoring.
Clarify intended use — Determine whether the goal is allergy immunotherapy repurposing or whether any individual botanical constituent (e.g., Echinacea for immunomodulation) is the true subject of investigation.
Re-submit as separate candidates — Each chemically distinct active ingredient should be submitted as its own evidence pack with a canonical INN and DrugBank ID.
Fill blocking data gaps — Retrieve MOA data (DG002) and package insert warnings (DG001) for whichever single-molecule constituents are selected for further evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.